Skip to main content

Table 1 Clinical and demographic characteristics of the study population

From: Hemodynamic effects of peri-operative statin therapy in on-pump cardiac surgery patients

  Statin No Statin p-value
(n = 276) (n = 202)  
Age and gender    
 Age (years) 68 ± 8.9 68 ± 10.9 0.94
 Male / Female (%) 69.2/30.8 59.9/40.1 0.03
Risk factors    
 Body mass index (kg/m²) 28 ± 4.7 27.1 ± 4.4 0.03
 Smokers (%) 39.9 27.7 0.006
 Hypertension (%) 77.5 68.8 0.03
 Diabetes mellitus (%) 37 23.3 0.001
 Positive family history (%) 13.4 4 0.11
 Ejection fraction (EF; %) 54 ± 14 53 ± 14 0.75
 Peripheral disease (%) 8.3 5 0.15
 Neurocerebral events (%) 12.3 12.4 0.98
 Pulmonary hypertension (%) 5.8 11.9 0.02
 COPD (%) 9.1 6.4 0.30
 Dialysis (%) 0.4 1 0.39
 Renal dysfunction (%) 14.5 13.4 0.73
Renal function variables    
 Serum creatinine (mg/dl) 1.17 ± 0.75 1.18 ± 0.74 0.82
 Urea (mg/dl) 22 ± 13 22 ± 13 0.54
 Estimated creatinine clearance (ml/min) 75 ± 32 77 ± 34 0.68
 Hematocrit (%) 40 ± 6 39 ± 6 0.31
Preoperative medications    
 ß-blockers (%) 67 61.4 0.20
 ACE inhibitors (%) 60.5 45 0.0008
 Oral nitrates (%) 22.5 13.9 0.02
 Antiarrhythmics (%) 4 3.5 0.76
 Diuretics (%) 40 43.1 0.48
 Antidiabetics (%) 21.7 14.9 0.06
 Further antihypertensives (%) 25.4 18.3 0.07
 Bronchodilator (%) 3.3 3 0.86
 Anticoagulation (%) 76.8 59.4 0.0001
Associated surgical procedures    
 CABG (n = 252 / 52.7%) (%) 68.1 31.7 <0.0001
 Valve (n = 107 / 22.4%) (%) 10.9 38.1 <0.0001
 Combined procedures (n = 101 / 21.1%) (%) 20.3 22.3 0.65
 Other procedures (n = 18 / 3.8%) (%) 0.7 7.9 <0.0001
Euroscore additive 5 ± 4 6 ± 4 0.29